NPHLA Tracker · GLP-1 & obesity drug pipeline (ClinicalTrials.gov)
GLP-1 & Obesity Drug Pipeline
Phase 2 and phase 3 clinical trials of GLP-1, amylin and other incretin-based obesity and metabolic medicines registered on ClinicalTrials.gov, with each study’s phase, recruitment status, sponsor and latest registry update.
- Pending editorial review
A system check is an automated check of the official sources, not a human review. An editorial review is recorded only when one of our editors has reviewed the page.
- Records
- 181
- Changed in 7 days
- 4
- Latest record
- Jurisdiction
- International / multiple
Records
181 recordsInvestigational therapies
Every therapy studied in a clinical trial is investigational and not approved for the use being studied. A trial’s phase and status describe the study, not whether the product works.
| Record | Status | Phase | Sponsor | Jurisdiction | Date | Source | Last checked |
|---|---|---|---|---|---|---|---|
| S-CUD: Semaglutide for the Treatment of Cannabis Use DisorderNCT07879612Conditions: Cannabis Use Disorder; Cue-reactivity. Interventions: semaglutide | Not yet recruiting | Phase 2 | Massachusetts General Hospital | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07879612 (opens in a new tab)Primary source | System checked NPHLA updated |
| The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 DiabetesNCT06976619Conditions: Type 1 Diabetes; Type 2 Diabetes. Interventions: Liraglutide Pen Injector; Saline Injections | Recruiting | Phase 2 | Mayo Clinic | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06976619 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 InhibitorNCT06221969Conditions: Type 2 Diabetes. Interventions: Cagrilintide; Semaglutide; Tirzepatide | Completed | Phase 3 | Novo Nordisk A/S | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06221969 (opens in a new tab)Primary source | System checked NPHLA updated |
| REIMAGINE 5: A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or BothNCT06534411Conditions: Diabetes Mellitus, Type 2. Interventions: Cagrilintide; Semaglutide; Tirzepatide | Completed | Phase 3 | Novo Nordisk A/S | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06534411 (opens in a new tab)Primary source | System checked NPHLA updated |
| REIMAGINEYOUNG: A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 DiabetesNCT07282613Conditions: Diabetes Mellitus, Type 2. Interventions: CagriSema (Cagrilintide B and Semaglutide I); Placebo matched to CagriSema (Cagrilintide B and Semaglutide I) | Recruiting | Phase 3 | Novo Nordisk A/S | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07282613 (opens in a new tab)Primary source | System checked NPHLA updated |
| ACHIEVE-2: A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With MetforminNCT06192108Conditions: Type 2 Diabetes. Interventions: Orforglipron; Dapagliflozin | Completed | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06192108 (opens in a new tab)Primary source | System checked NPHLA updated |
| Oral VK2735 for Weight Management Phase 3 (SUNRISE 1)NCT07868835Conditions: Weight Loss. Interventions: VK2735; Placebo comparator | Not yet recruiting | Phase 3 | Viking Therapeutics, Inc. | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07868835 (opens in a new tab)Primary source | System checked NPHLA updated |
| Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2)NCT07868939Conditions: Weight Loss. Interventions: VK2735 Oral; Placebo Comparator | Not yet recruiting | Phase 3 | Viking Therapeutics, Inc. | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07868939 (opens in a new tab)Primary source | System checked NPHLA updated |
| Aleniglipron Phase 2 Body Composition StudyNCT07169942Conditions: Obesity, Overweight, or Chronic Weight Management. Interventions: aleniglipron or placebo | Completed | Phase 2 | Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07169942 (opens in a new tab)Primary source | System checked NPHLA updated |
| SHORE: Semaglutide for Helping Opioid RecoveryNCT06639464Conditions: Opioid Use Disorder. Interventions: Semaglutide; Placebo | Recruiting | Phase 2 | Brigham and Women's Hospital | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06639464 (opens in a new tab)Primary source | System checked NPHLA updated |
| ELITE: ELITE: Deep Profiling and Algorithmic Polytherapy to Map Individual Response in Healthy AgingNCT07871799Conditions: Healthy Aging. Interventions: AgeBiotics AB-01; AgeBiotics AB-02; Metformin; semaglutide; empagliflozin | Completed | Phase 2 | Sheba Medical Center | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07871799 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Study of BGM0504 in Participants With Type 2 Diabetes in IndonesiaNCT07064486Conditions: Type 2 Diabetes (T2DM). Interventions: BGM0504; BGM0504; Semaglutide | Active, not recruiting | Phase 3 | BrightGene Bio-Medical Technology Co., Ltd. | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07064486 (opens in a new tab)Primary source | System checked NPHLA updated |
| ESSENCE: Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)NCT04822181Conditions: Non-alcoholic Steatohepatitis. Interventions: Semaglutide; Placebo | Active, not recruiting | Phase 3 | Novo Nordisk A/S | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT04822181 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Study of BGM0504 in Early T2DM With ObesityNCT07743983Conditions: Type 2 Diabetes (T2DM). Interventions: BGM0504; semaglutide | Recruiting | Phase 3 | BrightGene Bio-Medical Technology Co., Ltd. | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07743983 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Study of Weekly Oral Dose of Ecnoglutide (VRB-101) for Weight Maintenance in Participants Who Have Obesity or Overweight With Weight-Related ComorbiditiesNCT07553299Conditions: Obesity; Overweight; Weight Maintenance. Interventions: VRB-101; Placebo | Terminated | Phase 2 | Verdiva Bio Dev Limited | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07553299 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Study of BGM0504 in Participants With ObesityNCT06911203Conditions: Obesity. Interventions: BGM0504; Tirzepatide | Completed | Phase 2 | BrightGene Bio-Medical Technology Co., Ltd. | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06911203 (opens in a new tab)Primary source | System checked NPHLA updated |
| ATTAIN-CN: A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health ProblemsNCT07790861Conditions: Obesity; Overweight. Interventions: Orforglipron; Placebo | Not yet recruiting | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07790861 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 DiabetesNCT07215559Conditions: Obesity; Overweight; Diabetes Mellitus, Type 2. Interventions: Macupatide; Eloralintide; Macupatide Placebo; Eloralintide Placebo | Active, not recruiting | Phase 2 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07215559 (opens in a new tab)Primary source | System checked NPHLA updated |
| Tirzepatide for the Treatment of Cannabis Use DisorderNCT07265752Conditions: Cannabis Use Disorder. Interventions: Tirzepatide; Placebo | Not yet recruiting | Phase 2 | Brigham and Women's Hospital | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07265752 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)NCT07165028Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease. Interventions: Tirzepatide; Retatrutide; Placebo | Recruiting | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07165028 (opens in a new tab)Primary source | System checked NPHLA updated |
| The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)NCT06383390Conditions: Atherosclerotic Cardiovascular Disease (ASCVD); Chronic Kidney Disease (CKD). Interventions: Retatrutide; Placebo | Active, not recruiting | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06383390 (opens in a new tab)Primary source | System checked NPHLA updated |
| ACHIEVE-RAM: A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan FastingNCT07613307Conditions: Diabetes Mellitus, Type 2; Diabetes Melletus; Glucose Metabolism Disorders; Metabolic Disorders; Nutritional and Metabolic Diseases; Endocr…. Interventions: Orforglipron | Recruiting | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07613307 (opens in a new tab)Primary source | System checked NPHLA updated |
| ATTAIN-OA PAIN: A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the KneeNCT07153471Conditions: Osteoarthritis. Interventions: Orforglipron; Placebo | Active, not recruiting | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07153471 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 DiabetesNCT07668388Conditions: Diabetes Mellitus, Type 2. Interventions: UBT251; UBT251 Placebo; Semaglutide; Semaglutide Placebo | Recruiting | Phase 2 | Novo Nordisk A/S | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07668388 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or OverweightNCT06143956Conditions: Obesity; Overweight. Interventions: LY3305677; LY3841136; Tirzepatide; LY3549492; LY3532226; Placebo; Placebo | Recruiting | Phase 2 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06143956 (opens in a new tab)Primary source | System checked NPHLA updated |
| RENEW 2: Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With CagrilintideNCT07220759Conditions: Overweight; Obesity; Type 2 Diabetes. Interventions: Cagrilintide; Placebo (matched to Cagrilintide) | Active, not recruiting | Phase 3 | Novo Nordisk A/S | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07220759 (opens in a new tab)Primary source | System checked NPHLA updated |
| STEP Young: A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose WeightNCT05726227Conditions: Obesity. Interventions: Semaglutide; Placebo | Active, not recruiting | Phase 3 | Novo Nordisk A/S | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT05726227 (opens in a new tab)Primary source | System checked NPHLA updated |
| FOCUS: A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 DiabetesNCT03811561Conditions: Diabetes Mellitus, Type 2. Interventions: Semaglutide; Placebo (semaglutide) | Active, not recruiting | Phase 3 | Novo Nordisk A/S | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT03811561 (opens in a new tab)Primary source | System checked NPHLA updated |
| Semaglutide in Women With Polycystic Ovary Syndrome and ObesityNCT06896981Conditions: Polycystic Ovary Syndrome (PCOS) Women; Obesity. Interventions: Metformin with Semaglutide | Completed | Phase 2 / Phase 3 | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06896981 (opens in a new tab)Primary source | System checked NPHLA updated |
| KaiNETIC-3: Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have DiabetesNCT07284979Conditions: Obesity. Interventions: Ribupatide; Semaglutide; Placebo | Active, not recruiting | Phase 3 | Kailera | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07284979 (opens in a new tab)Primary source | System checked NPHLA updated |
| KaiNETIC-1: Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have DiabetesNCT07284875Conditions: Obesity; Overweight. Interventions: Ribupatide; Placebo | Active, not recruiting | Phase 3 | Kailera | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07284875 (opens in a new tab)Primary source | System checked NPHLA updated |
| KaiNETIC-2: Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and DiabetesNCT07284901Conditions: Obesity With Diabetes; Overweight With Diabetes. Interventions: Ribupatide; Placebo | Active, not recruiting | Phase 3 | Kailera | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07284901 (opens in a new tab)Primary source | System checked NPHLA updated |
| CAPTIVATE: The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic EffectNCT06058585Conditions: Chronic Kidney Diseases. Interventions: Finerenone; Placebo Finerenone; Semaglutide; Placebo semaglutide | Recruiting | Phase 3 | The George Institute | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06058585 (opens in a new tab)Primary source | System checked NPHLA updated |
| The Effect of Oral Semaglutide on Bone Turnover in Patients With T2D: a Randomized Placebo-controlled Clinical TrialNCT06050577Conditions: Type 2 Diabetes; Osteopenia. Interventions: oral Semaglutide/Rybelsus; Placebo | Active, not recruiting | Phase 2 | Odense University Hospital | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06050577 (opens in a new tab)Primary source | System checked NPHLA updated |
| WE-FiERCE: Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Low-grade Cancer of the EndometriumNCT06073184Conditions: Endometrial Cancer; Atypical Hyperplasia; Fertility Perservation. Interventions: Wegovy; Mirena | Recruiting | Phase 2 | GynOncTrials | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06073184 (opens in a new tab)Primary source | System checked NPHLA updated |
| TP04HN106 in the Treatment of Patients With Amyotrophic Lateral SclerosisNCT06726577Conditions: Amyotrophic Lateral Sclerosis. Interventions: TP04HN106; Saline | Recruiting | Phase 1 / Phase 2 | Talengen Institute of Life Sciences, Shenzhen, P.R. China. | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06726577 (opens in a new tab)Primary source | System checked NPHLA updated |
| Combination Therapy for Alcohol Use DisorderNCT07249554Conditions: Alcohol Use Disorder. Interventions: Placebo; Glucagon-Like Peptide-1 Agonist (GLP-1); Naltrexone (oral tablets) | Not yet recruiting | Phase 2 | Johns Hopkins University | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07249554 (opens in a new tab)Primary source | System checked NPHLA updated |
| SWIFT: Semaglutide, Weight Loss, and LNG-IUD for Conservative Treatment of Endometrial Atypical Hyperplasia and Grade 1 Endometrial CancerNCT07820358Conditions: Endometrial Atypical Hyperplasia; Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia; Endometrial Cancer Stage I; Endo…. Interventions: Semaglutide (Wegovy) weekly injection; LNG-IUD (Progestin); Structured Weight Loss Program | Not yet recruiting | Phase 2 | The Methodist Hospital Research Institute | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07820358 (opens in a new tab)Primary source | System checked NPHLA updated |
| ACHIEVE-5: A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 InhibitorNCT06109311Conditions: Type 2 Diabetes. Interventions: Orforglipron; Placebo | Completed | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06109311 (opens in a new tab)Primary source | System checked NPHLA updated |
| GATA-3: Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3)NCT05254314Conditions: Asthma. Interventions: Semaglutide Pen Injector 2.4mg weekly; Placebo | Active, not recruiting | Phase 2 | Vanderbilt University Medical Center | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT05254314 (opens in a new tab)Primary source | System checked NPHLA updated |
| REIMAGINE 1: A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and ExerciseNCT06323174Conditions: Type 2 Diabetes. Interventions: Cagrilintide; Semaglutide; Placebo | Completed | Phase 3 | Novo Nordisk A/S | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06323174 (opens in a new tab)Primary source | System checked NPHLA updated |
| Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to CagrisemaNCT07817251Conditions: Diabetes Mellitus, Type 2. Interventions: CagriSema | Recruiting | Phase 3 | Novo Nordisk A/S | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07817251 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-termNCT07011667Conditions: Obesity. Interventions: CagriSema (Cagrilintide B and Semaglutide I); Placebo matched to CagriSema (Cagrilintide B and Semaglutide I) | Active, not recruiting | Phase 3 | Novo Nordisk A/S | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07011667 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose WeightNCT07564414Conditions: Obesity; Type 2 Diabetes. Interventions: Cagrisema; Semaglutide | Recruiting | Phase 3 | Novo Nordisk A/S | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07564414 (opens in a new tab)Primary source | System checked NPHLA updated |
| DEFINE: A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxinNCT03449251Conditions: Cardiovascular Diseases; Type 2 Diabetes Mellitus. Interventions: Apelin; Relaxin; Normal saline; Verapamil; LN Monomethyl arginine | Active, not recruiting | Phase 2 | Cambridge University Hospitals NHS Foundation Trust | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT03449251 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body WeightNCT07253285Conditions: Overweight; Obesity. Interventions: Cagrilintide; Semaglutide; Placebo cagrilintide; Placebo semaglutide | Recruiting | Phase 3 | Novo Nordisk A/S | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07253285 (opens in a new tab)Primary source | System checked NPHLA updated |
| REDEFINE 1: A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose WeightNCT05567796Conditions: Obesity. Interventions: Cagrilintide; Semaglutide; Placebo cagrilintide; Placebo semaglutide | Active, not recruiting | Phase 3 | Novo Nordisk A/S | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT05567796 (opens in a new tab)Primary source | System checked NPHLA updated |
| Phase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in ObesityNCT06771115Conditions: Obesity. Interventions: Placebo; VTX3232 30 mg; Placebo in combination with semaglutide; VTX3232 30 mg in combination with semaglutide | Completed | Phase 2 | Zomagen Biosciences Ltd. | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06771115 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLDNCT07527910Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Interventions: ALN-PNP; Tirzepatide; Placebo | Recruiting | Phase 2 | Regeneron Pharmaceuticals | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07527910 (opens in a new tab)Primary source | System checked NPHLA updated |
| TOLEDDO: Effect of Weekly GLP1 Agonist Treatment in "Double Diabetes"NCT05305794Conditions: Double Diabetes. Interventions: Insulin + semaglutide treatment; Usual insulin treatment; Biological check-up | Recruiting | Phase 3 | Centre Hospitalier Universitaire Dijon | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT05305794 (opens in a new tab)Primary source | System checked NPHLA updated |
How is this tracker compiled?
The Intelligence pipeline queries the ClinicalTrials.gov API (version 2) on the schedule set in the Source Registry: one broad search for obesity and incretin therapies (GLP-1, semaglutide, tirzepatide, retatrutide, orforglipron, amylin, cagrilintide, survodutide) and a separate search for each metabolic topic that has a trial query, such as retatrutide or orforglipron. Each study is stored with its registry fields exactly as published: title, phase, overall status, sponsor, conditions, interventions and the date of its last registry update.
When a study’s overall status changes, or results are first posted, the change is recorded with the date the pipeline detected it. This tracker lists studies on the Metabolic desk whose registered phase includes phase 2 or phase 3 (combined phase 2/3 studies included). Nothing in the table is edited by hand.
Selection: ClinicalTrials.gov studies followed by Trial Watch in phase 2 and phase 3 on the metabolic desk.
What does it cover?
Studies listed on ClinicalTrials.gov — from the United States and other countries — that match the search terms above, from the date tracking of each search began. Phase 2 and phase 3 only. Phase 1 and phase 4 studies, studies described with other terms and studies registered only in other registries are not included.
What are its limitations?
Registry records are maintained by trial sponsors and can lag events; the status shown is the sponsor’s registry status at the last check, not an assessment of the trial. Searches can include studies of these medicines for conditions other than obesity and can miss studies that use different terms. Every therapy in a trial is investigational for the use being studied. Not medical advice.
How often is it updated?
Registry searches run every 6 to 12 hours, as configured in the Source Registry; the table reflects each completed check.
System checked is the last time an automated check of the underlying official sources succeeded — it is not a human review. Editorially reviewed appears only when an editor has reviewed this tracker. Each row shows its own check: an automated system check or an editor’s verification.
Data origin: NPHLA analysis of public data. Professional reference only — not medical, legal or regulatory advice. Always confirm a record in its primary source. Spotted an error? Tell us.